A detailed history of Rhumbline Advisers transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 64,535 shares of KYMR stock, worth $3.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,535
Previous 57,392 12.45%
Holding current value
$3.22 Million
Previous $2.31 Million 16.51%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$29.85 - $39.42 $213,218 - $281,577
7,143 Added 12.45%
64,535 $1.93 Million
Q1 2024

May 09, 2024

BUY
$22.9 - $43.57 $89,058 - $169,443
3,889 Added 7.27%
57,392 $2.31 Million
Q4 2023

Feb 08, 2024

SELL
$10.97 - $26.84 $1,360 - $3,328
-124 Reduced 0.23%
53,503 $1.36 Million
Q3 2023

Nov 09, 2023

SELL
$13.9 - $23.88 $236 - $405
-17 Reduced 0.03%
53,627 $745,000
Q2 2023

Aug 08, 2023

SELL
$22.4 - $34.92 $230,339 - $359,082
-10,283 Reduced 16.09%
53,644 $1.23 Million
Q1 2023

May 11, 2023

BUY
$24.84 - $38.75 $67,241 - $104,896
2,707 Added 4.42%
63,927 $1.89 Million
Q4 2022

Feb 14, 2023

BUY
$19.57 - $30.92 $19,433 - $30,703
993 Added 1.65%
61,220 $1.53 Million
Q3 2022

Nov 10, 2022

BUY
$20.91 - $34.27 $111,638 - $182,967
5,339 Added 9.73%
60,227 $1.31 Million
Q2 2022

Aug 11, 2022

BUY
$14.13 - $42.55 $263,948 - $794,834
18,680 Added 51.59%
54,888 $1.08 Million
Q1 2022

May 12, 2022

BUY
$35.3 - $64.68 $87,579 - $160,471
2,481 Added 7.36%
36,208 $1.53 Million
Q4 2021

Feb 10, 2022

BUY
$49.91 - $65.56 $23,657 - $31,075
474 Added 1.43%
33,727 $2.14 Million
Q3 2021

Nov 12, 2021

BUY
$47.8 - $66.66 $272,268 - $379,695
5,696 Added 20.67%
33,253 $1.95 Million
Q2 2021

Aug 05, 2021

BUY
$31.08 - $51.95 $501,662 - $838,524
16,141 Added 141.39%
27,557 $1.34 Million
Q1 2021

May 06, 2021

BUY
$35.64 - $85.46 $32,967 - $79,050
925 Added 8.82%
11,416 $444,000
Q4 2020

Feb 10, 2021

BUY
$28.07 - $87.83 $294,482 - $921,424
10,491 New
10,491 $650,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.73B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.